Company profile
Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07020117 | phase1 | recruiting | 2025-08-22 | 2027-12-01 | Aktis Oncology, Inc. | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors |
| NCT07581184 | phase1 | recruiting | 2026-07-01 | 2027-12-01 | Aktis Oncology, Inc. | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer |
FDA applications (0)
No records yet.